Welcome to our dedicated page for NATURES SUNSHINE PRODUCTS SEC filings (Ticker: NATR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NATURES SUNSHINE PRODUCTS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NATURES SUNSHINE PRODUCTS's regulatory disclosures and financial reporting.
Nature's Sunshine Products, Inc. (NATR) – Form 144 filing discloses that insider Richard D. Moss Revocable Trust intends to sell 1,000 common shares through broker Wells Fargo Clearing Services on or about 07 July 2025. Based on the reference price in the notice, the proposed transaction is valued at $15,931.15. The filing shows 18,350,801 shares outstanding; the planned sale therefore represents roughly 0.005 % of outstanding shares.
More importantly, the trust and Richard D. Moss have been active sellers during the past three months. The table included in the filing lists 18 separate transactions between 9 May 2025 and 7 July 2025, totaling 46,234 shares and generating gross proceeds of approximately $675,514. This cumulative amount equals about 0.25 % of the company’s shares outstanding. While neither the filing nor Rule 144 requires disclosure of motives, sustained insider selling can be interpreted by some investors as a signal of reduced near-term confidence or personal diversification.
The shares to be sold were originally acquired via restricted share grants and compensation on 6 May 2024; no cash outlay or special consideration was involved. The signatory certifies that no material non-public adverse information is known at the time of filing.
Takeaways for investors:
- The upcoming 1,000-share sale is immaterial in isolation, but it comes after a pattern of sizable disposals by the same beneficial owner.
- Total insider sales of >46 k shares in three months, although small relative to float, may draw attention to management’s sentiment and potential supply overhang.
- No operational or financial performance data are included; the filing is solely a notice of proposed sales under Rule 144.
Nature’s Sunshine Products Inc. (NATR) – Form 4 insider transaction filed 27 June 2025
The filing discloses that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") and its wholly-owned subsidiary Fosun Pharma USA Inc.—both classified as 10 % owners—sold 2,854,607 shares of NATR common stock on 27 June 2025. The disposition, coded “S”, was executed at a reported price of $11.46 per share pursuant to an Underwriting Agreement dated 25 June 2025.
- Post-transaction holdings: Fosun Pharma USA Inc. now reports 0 shares; Fosun Pharma’s remaining indirect ownership is 64,167 shares held through another wholly-owned subsidiary, Fosun Industrial Co., Limited.
- Percentage change: The sale represents > 97 % reduction in Fosun’s reported stake, effectively eliminating its direct position.
- No derivative securities were reported.
The filing signals a material reduction of a long-standing 10 % shareholder’s position, increasing NATR’s public float and potentially altering future governance dynamics. No earnings or operational data are included in this Form 4.